[go: up one dir, main page]

WO2001093829A3 - Powder compositions - Google Patents

Powder compositions Download PDF

Info

Publication number
WO2001093829A3
WO2001093829A3 PCT/US2001/018494 US0118494W WO0193829A3 WO 2001093829 A3 WO2001093829 A3 WO 2001093829A3 US 0118494 W US0118494 W US 0118494W WO 0193829 A3 WO0193829 A3 WO 0193829A3
Authority
WO
WIPO (PCT)
Prior art keywords
drying
powder
compositions
prepared
spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/018494
Other languages
French (fr)
Other versions
WO2001093829A2 (en
Inventor
Yuh-Fun Maa
Lu Zhao
Steven Joseph Prestrelski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Vaccines Inc
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Priority to BR0111494-8A priority Critical patent/BR0111494A/en
Priority to AU2001275371A priority patent/AU2001275371B9/en
Priority to MXPA02012039A priority patent/MXPA02012039A/en
Priority to EP01942075A priority patent/EP1289494A2/en
Priority to IL15324101A priority patent/IL153241A0/en
Priority to JP2002501402A priority patent/JP2003535119A/en
Priority to NZ523103A priority patent/NZ523103A/en
Priority to CA002412197A priority patent/CA2412197A1/en
Publication of WO2001093829A2 publication Critical patent/WO2001093829A2/en
Publication of WO2001093829A3 publication Critical patent/WO2001093829A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

A gel-forming free-flowing powder suitable for use as a vaccine is prepared by spray-drying or spray freeze-drying an aqueous suspension that contains an antigen adsorbed to an aluminum salt or calcium salt adjuvant, a saccharide, an amino acid or a salt thereof, and a colloidal substance. Powder for vaccine purposes are also prepared by spray freeze-drying an aqueous suspension of such an adjuvant having an antigen adsorbed therein. Processes for forming these powder compositions are also described, as well as methods of using the compositions in a vaccination procedure.
PCT/US2001/018494 2000-06-08 2001-06-08 Powder compositions Ceased WO2001093829A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR0111494-8A BR0111494A (en) 2000-06-08 2001-06-08 Gel-forming free-flowing powder suitable for use as a vaccine, process for preparing it, dosage container for a needleless syringe, needleless syringe, vaccine composition, method for vaccinating an individual, suitable powder for use as a vaccine. a vaccine, and process for preparing it
AU2001275371A AU2001275371B9 (en) 2000-06-08 2001-06-08 Powder compositions
MXPA02012039A MXPA02012039A (en) 2000-06-08 2001-06-08 Powder compositions.
EP01942075A EP1289494A2 (en) 2000-06-08 2001-06-08 Powder compositions
IL15324101A IL153241A0 (en) 2000-06-08 2001-06-08 Powder compositions
JP2002501402A JP2003535119A (en) 2000-06-08 2001-06-08 Powder composition
NZ523103A NZ523103A (en) 2000-06-08 2001-06-08 Salt adjuvant-containing vaccine freeze-dried compositions in a powder form for transdermal delivery from a needless syringe
CA002412197A CA2412197A1 (en) 2000-06-08 2001-06-08 Powder compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21058100P 2000-06-08 2000-06-08
US59077700A 2000-06-08 2000-06-08
US09/590,777 2000-06-08
US60/210,581 2000-06-08

Publications (2)

Publication Number Publication Date
WO2001093829A2 WO2001093829A2 (en) 2001-12-13
WO2001093829A3 true WO2001093829A3 (en) 2002-06-13

Family

ID=26905296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/018494 Ceased WO2001093829A2 (en) 2000-06-08 2001-06-08 Powder compositions

Country Status (11)

Country Link
EP (1) EP1289494A2 (en)
JP (1) JP2003535119A (en)
KR (1) KR20030020294A (en)
CN (1) CN1438874A (en)
AU (1) AU2001275371B9 (en)
BR (1) BR0111494A (en)
CA (1) CA2412197A1 (en)
IL (1) IL153241A0 (en)
MX (1) MXPA02012039A (en)
NZ (2) NZ552576A (en)
WO (1) WO2001093829A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229645B2 (en) 2001-06-08 2007-06-12 Powderject Research Limited Spray freeze-dried compositions
CN1607941A (en) * 2001-11-19 2005-04-20 贝克顿迪肯森公司 Pharmaceutical compositions in particulate form
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
JP2008514644A (en) * 2004-09-28 2008-05-08 アルザ コーポレイション Stabilization of alum adjuvant immunoactive agent
AU2006261669B2 (en) * 2005-06-27 2011-07-07 Applied Thin Films, Inc. Aluminum phosphate based microspheres
KR20080059289A (en) 2005-10-04 2008-06-26 알크-아벨로 에이/에스 Solid vaccine formulation
EP1945249A2 (en) * 2005-11-01 2008-07-23 Novartis AG Compositions with antigens adsorbed to calcium phosphate
EP2068834A2 (en) * 2006-09-08 2009-06-17 Becton, Dickinson & Company Stable powder formulations of aluma-dsorbed vaccines
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
US8444991B2 (en) 2007-03-22 2013-05-21 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
BRPI0814594A2 (en) * 2007-07-26 2015-01-20 Sanofi Pasteur Ltd ADJUVANT ANTIGEN COMPOSITIONS AND METHODS
MX2010008799A (en) * 2008-03-05 2010-09-07 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition.
WO2010038076A1 (en) 2008-10-02 2010-04-08 Pharmathene Uk Limited Anthrax vaccine formulation and uses thereof
CA2795047C (en) 2010-03-31 2019-04-09 Stabilitech Ltd. Stabilised liquid formulations
EP2898890B1 (en) 2010-03-31 2019-08-21 Stabilitech Biopharma Ltd Stabilisation of viral particles
KR101819250B1 (en) 2010-03-31 2018-01-16 스타빌리테크 리미티드 Method for preserving alum adjuvants and alum-adjuvanted vaccines
BR112013010926A2 (en) 2010-11-01 2016-08-23 Univ Technology Sidney immunomodulatory agents and their uses
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
WO2012075376A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
CN102133396B (en) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 Vaccine injection and preparation method thereof
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
US12447127B2 (en) 2011-05-17 2025-10-21 The Regents Of The University Of Colorado, A Body Corporate Thermostable vaccine compositions and methods of preparing the same
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
WO2013133702A1 (en) * 2012-03-05 2013-09-12 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Methods and compositions for stabilizing dried biological materials
KR101441539B1 (en) * 2013-04-01 2014-09-18 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 Adhesive compositions having improved hygroscopicity and preparation methods thereof
CN103641886B (en) * 2013-11-26 2015-07-29 精晶药业股份有限公司 A kind of process for purification of glutamine dipeptide
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
GB202400295D0 (en) * 2024-01-09 2024-02-21 Stablepharma Ltd Hypertonic thermostable vaccine compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0065905A1 (en) * 1981-05-13 1982-12-01 Institut Pasteur Stabilizing agents for live viruses for the preparation of vaccines, and stabilized vaccines containing these stabilizing agents
GB2135190A (en) * 1983-02-22 1984-08-30 Human Oltoanyagtermelo Lyophilized adsorbed polyvalent vaccines
EP0130619A2 (en) * 1983-07-05 1985-01-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Hepatitis B vaccine and method for its preparation
WO1994015636A1 (en) * 1993-01-08 1994-07-21 Csl Limited Vaccine preparations
US5630796A (en) * 1993-04-08 1997-05-20 Oxford Biosciences Limited Method of delivering powder transdermally with needless injector
RU2096042C1 (en) * 1996-11-06 1997-11-20 Виктор Иванович Ситьков Method of preparing multipartial vaccine for leptospirosis control in animals

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0676088A1 (en) * 1992-12-28 1995-10-11 YU, Shih-Chiang Non-volatile semiconductor memory cell
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
HUP0101139A3 (en) * 1997-12-02 2003-11-28 Powderject Vaccines Inc Madiso Transdermal delivery of particulate vaccine compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0065905A1 (en) * 1981-05-13 1982-12-01 Institut Pasteur Stabilizing agents for live viruses for the preparation of vaccines, and stabilized vaccines containing these stabilizing agents
GB2135190A (en) * 1983-02-22 1984-08-30 Human Oltoanyagtermelo Lyophilized adsorbed polyvalent vaccines
EP0130619A2 (en) * 1983-07-05 1985-01-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Hepatitis B vaccine and method for its preparation
WO1994015636A1 (en) * 1993-01-08 1994-07-21 Csl Limited Vaccine preparations
US5630796A (en) * 1993-04-08 1997-05-20 Oxford Biosciences Limited Method of delivering powder transdermally with needless injector
RU2096042C1 (en) * 1996-11-06 1997-11-20 Виктор Иванович Ситьков Method of preparing multipartial vaccine for leptospirosis control in animals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199828, Derwent World Patents Index; Class B04, AN 1998-320414, XP002195515 *

Also Published As

Publication number Publication date
EP1289494A2 (en) 2003-03-12
JP2003535119A (en) 2003-11-25
WO2001093829A2 (en) 2001-12-13
CN1438874A (en) 2003-08-27
IL153241A0 (en) 2003-07-06
CA2412197A1 (en) 2001-12-13
AU2001275371B2 (en) 2006-12-21
AU7537101A (en) 2001-12-17
AU2001275371B9 (en) 2007-06-07
MXPA02012039A (en) 2003-06-06
NZ552576A (en) 2008-06-30
KR20030020294A (en) 2003-03-08
NZ523103A (en) 2005-08-26
BR0111494A (en) 2004-01-13

Similar Documents

Publication Publication Date Title
WO2001093829A3 (en) Powder compositions
WO2001060402A3 (en) Proteosome influenza vaccine
ES2313881T3 (en) FORMULATIONS OF VACCINES FRONT OF THE HUMAN PAPILOMAVIRUS.
GB0118249D0 (en) Histidine vaccines
FI3246044T4 (en) Stable formulations of neisseria meningitidis rlp2086 antigens
JP2000502672A (en) Live vaccine stabilizer
WO2000023105A3 (en) Adjuvant systems and vaccines
EP2368573A3 (en) Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2004001007A3 (en) Buffered formulations for concentrating antibodies and methods of use thereof
WO2004000351A8 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
HUP0303278A2 (en) Freeze-dried pantoprazole preparation, process for its preparation and pantoprazole injection
AU2011234268B2 (en) Method for preserving alum adjuvants and alum-adjuvanted vaccines
WO2008079464A3 (en) Stable powder formulations of alum-adsorbed vaccines
HK1043943A1 (en) Streptococcus pneumoniae proteins and vaccines
WO2000062801A3 (en) Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
CA2282779A1 (en) Formulation comprising an antigen, an adjuvant and an amino acid for use in immunization.
AU2008225501A1 (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
JP2004505992A5 (en)
Hem et al. Aluminum-containing adjuvants: properties, formulation, and use
WO2003005989A3 (en) Granulates containing liposoluble substances and a process for the preparation thereof
WO2004073652A3 (en) Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
WO2023172741A3 (en) A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine comprising b- and t-cell antigens, immunogenic composition, and uses thereof
JP2017509713A5 (en)
WO2002036160A3 (en) Method for obtaining antigenic structures enhancing specific cross reactivity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 153241

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012039

Country of ref document: MX

Ref document number: IN/PCT/2002/2012/CHE

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2002 501402

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027016801

Country of ref document: KR

Ref document number: 2412197

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 523103

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001275371

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018117457

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001942075

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027016801

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001942075

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 523103

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523103

Country of ref document: NZ